Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Jan 19;17(1):e77681.
doi: 10.7759/cureus.77681. eCollection 2025 Jan.

Successful Treatment of a Patient With Chronic Bronchiectasis Using an Induced Native Phage Cocktail: A Case Report

Affiliations
Case Reports

Successful Treatment of a Patient With Chronic Bronchiectasis Using an Induced Native Phage Cocktail: A Case Report

David A Jernigan et al. Cureus. .

Abstract

Bronchiectasis is a well-recognized chronic respiratory disease characterized by a productive cough and multi-microbial activation syndrome (MMAS) of various respiratory infections due to what can be the permanent dilatation of the bronchi. Bronchiectasis represents an ongoing challenge to conventional antibiotic treatment as the damaged bronchial environment remains conducive to ongoing opportunistic infections and microbial mutations, leading to multi-drug resistance. Standard treatment guidelines are designed to promptly identify and address the primary infection. Despite the strong focus on identification of the primary infection in each new episode, by combining clinical history, and high-resolution computed tomography (HRCT), a high proportion of patients remain classified as "idiopathic". Important underlying infections, such as Aspergillus and other mold infections, Pseudomonas aeruginosa, Mycobacterium, Mycoplasma, and various viruses, are frequently not identified for prolonged periods of time, and selected broad-spectrum antibiotics are often ineffective. The introduction of Induced Native Phage Therapy in 2021 and Induced Native Phage cocktails in 2024 provides a new treatment alternative that induces naturally occurring phages to eliminate specifically targeted acute and chronic mixed infections even in cases of multi-drug resistant infections as seen in chronic bronchiectasis. This article will present the successful long-term results in a case study demonstrating the speed, gentleness, and effectiveness of induced native phage cocktails in a 45-year-old male with life-long asthma resulting in multi-microbial activation syndrome in severe non-cystic fibrosis bronchiectasis for the last 20 years.

Keywords: aspergillus; asthma; biofilm; bronchiectasis; endotoxin; induced native phage therapy; multi-microbial activation syndrome; mycobacterium; pseudomonas aeruginosa; staphylococcus.

PubMed Disclaimer

Conflict of interest statement

Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. Advarra issued approval Pro00064096. The single-site protocol titled, "The INPT/CMABM Registry: An Observational Study of the Dietary Supplement, Induced Native Phage Therapy, Combined with the Treatment Philosophies and Techniques of Chiropractic Medicine and American Biological/Bioregulatory Medicine (CMABM) has been approved to proceed. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: David A. Jernigan declare(s) employment from PhagenCorp. David A. Jernigan is the inventor of INPT (patent-pending), the owner of PhagenCorp, which produces the Inducen formulations, and the owner of the site for the IRB study, Biologix Center for Optimum Health, Franklin, Tennessee, U.S.A. Intellectual property info: Induced Native Phage Therapy (INPT) is presently patent-pending. Inducen formulations are copyright protected. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Similar articles

Cited by

References

    1. The Top 10 Causes of Death. 2024. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
    1. An update on bronchiectasis. Moreschi MA, Fiel SB. https://journals.lww.com/co-pulmonarymedicine/abstract/1995/03000/an_upd.... Curr Opin Pulm Med. 1995;1:119–124. - PubMed
    1. Bird K, Memon J. StatPearls [Internet] Treasure Island: StatPearls Publishing; 2024. Bronchiectasis.
    1. Bacteriophages for bronchiectasis: treatment of the future? Dominic C, Pye HV, Mishra EK, Adriaenssens EM. Curr Opin Pulm Med. 2024;1:235–242. - PubMed
    1. Designing phage cocktails to combat the emergence of bacteriophage-resistant mutants in multidrug-resistant Klebsiella pneumoniae. Yoo S, Lee K-M, Kim N, Vu TN, Abadie R, Yong D. Microbiol Spectr. 2024;12:0. - PMC - PubMed

Publication types

LinkOut - more resources